# 3D Imaging Drug Design and Development – FDA Inspection, Jan 18, 2019

Source: https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/fa006bb2-0ae3-48d4-a205-c84f0d757d0a
Source feed: FDA_Inspections

> FDA inspection 1076821 of 3D Imaging Drug Design and Development, January 18, 2019. Classification: Voluntary Action Indicated (VAI). 6 citations under 21 CFR part 212. Form 483 issued. 3 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1076821
- Company Name: 3D Imaging Drug Design and Development
- Inspection Date: 2019-01-18
- Classification: Voluntary Action Indicated (VAI)
- Classification Code: VAI
- Project Area: Generic Drug Evaluation
- Product Type: Human Drugs
- Center: Human Drugs
- Office Name: Dallas District Office
- Citation Count: 6

## Related Documents

- [FDA Inspection 1272748 - 2025-06-13](https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/110c05b6-92ad-4ba6-a7b3-089d7293b2a5)
- [FDA Inspection 1228168 - 2024-01-31](https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/b62a272a-50d6-4a9e-99be-3d3008f0eb1d)
- [FDA Inspection 1009371 - 2017-04-20](https://www.keypedia.com/records/fda_inspections/3d-imaging-drug-design-and-development/64a48028-799f-499d-8317-f10bb4b44bfe)

## Related Officers

- [FDA Associated Person](https://www.keypedia.com/people/margaret-m-annes/e528fbbe-2a4c-4697-9256-b7f2d0bcd279)

Company: https://www.keypedia.com/companies/3d-imaging-drug-design-and-development/52a34c85-0fab-4e15-8980-ba031bb418ce

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9